Drug intelligence / Profile preview

BI 1060469

Development stage: Phase 1
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 1060469 is a small molecule drug that acts as a CRTH2 antagonist, targeting the chemo-attractant receptor-homologous molecule on T-helper-2 cells. It is primarily developed for immune system diseases and respiratory diseases, including asthma, by inhibiting prostaglandin D2 (PGD2) binding to CRTH2. The drug is developed by Boehringer Ingelheim.

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on BI 1060469.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1060469.

Explore the full profile